GlassScriptPhysician profile
Maninder S Kahlon
NPI 1184695165
$20,509.01
in general payments reported to CMS, 2019-2025
72 companies · $3,970 in 2025
The $3,970 reported for 2025 was more than what 82% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,483 · 2020: $2,288 · 2021: $2,717 · 2022: $2,596 · 2023: $3,753 · 2024: $2,702 · 2025: $3,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $228 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $60.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,136.90 |
| Education | $227.74 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $60.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $2,044.98 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Abbvie INC. | $1,515.82 | 2021-2025 | |
| Sk Life Science, INC. | $1,317.35 | 2020-2025 | Xcopri |
| Genentech USA, INC. | $1,270.14 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Teva Pharmaceuticals USA, INC. | $1,173.64 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amneal Pharmaceuticals LLC | $1,160.00 | 2019-2025 | Rytary, Crexont, Lyvispah |
| Novartis Pharmaceuticals Corporation | $1,076.85 | 2019-2025 | |
| Acadia Pharmaceuticals INC | $968.96 | 2019-2025 | Nuplazid |
| Argenx US, INC. | $943.94 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $843.21 | 2019-2024 | Ultomiris |
| Pfizer INC. | $678.89 | 2019-2025 | |
| Biogen, INC. | $580.06 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Eisai INC. | $498.02 | 2019-2025 | |
| Abbott Laboratories | $482.92 | 2019-2024 | Infinity, Proclaim |
| Amgen INC. | $456.56 | 2019-2025 | Uplizna |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maninder Kahlon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.